

# Lung Cancer; A Literature Review

*by Yan Efrata Sembiring*

---

**Submission date:** 11-May-2024 06:26AM (UTC+0800)

**Submission ID:** 2376376338

**File name:** Lung\_Cancer\_A\_Literature\_Review.pdf (524.74K)

**Word count:** 3222

**Character count:** 17287

## LITERATURE REVIEW

## Lung Cancer: A Literature Review

Yan Efrata Sembiring<sup>1</sup>, Wiwin Is Effendi<sup>2</sup>, Jeffrey Jeswant Dillon<sup>3</sup>, Heroe Soebroto<sup>1</sup>,  
 Dhihintia Jiwangga Suta Winarno<sup>1</sup>, Puruhito Puruhito<sup>1</sup>, I Gusti Agung Made Adnyanya Putra Putra<sup>1</sup>,  
 Abed Nego Okthara Sebayang<sup>1</sup>, Sri Pramesti Wisnu Bowo Negoro<sup>1</sup>

<sup>1</sup>Department of Thoracic, Cardiac, and Vascular Surgery, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya, Indonesia.

<sup>2</sup>Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya, Indonesia.

<sup>3</sup>Department of Cardiothoracic Surgery, Institut Jantung Negara, Kuala Lumpur, Malaysia.

## ARTICLE INFO

## Article history:

Received 29 June 2023

Received in revised form

8 September 2023

Accepted 30 September 2023

Available online 30 September 2023

## Keywords:

Cancer,

Carcinoma,

Lung cancer,

Non-small cell carcinoma,

Small cell lung carcinoma.

## Cite this as:

Sembiring YE, Effendi WI, Dillon JJ, et al. Lung Cancer: A Literature Review. *J Respi* 2023; 9: 246-251.

## ABSTRACT

Lung cancer is a cancer whose onset starts in the lungs where there is an abnormal cell growth that is very fast and uncontrolled. The abnormal cell growth is triggered by deoxyribonucleic acid (DNA) damage, including deletions in the DNA section, inactivation of tumor suppressor genes, activation of proto-oncogenes to oncogenes, the absence of apoptosis, and the activity of the telomerase enzyme. Lung cancer is initiated by oncogene activity and inactivation of tumor suppressor genes. Oncogenes are genes that help cells grow and divide and are believed to cause a person to develop lung cancer. In general, lung cancer is divided into two types, namely non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). World Health Organization (WHO) classifies lung cancer based on histopathology into 4 major cell types, namely SCLC, NSCLC which includes adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma (LCC). The difference between the two is that SCLC has a higher aggressiveness than NSCLC. Cancer treatment is based on the type, size, location and stage of the cancer, as well as the patient's overall condition.

## INTRODUCTION

Lung cancer is a cancer whose onset starts in the lungs where there is an abnormal cell growth that is very fast and uncontrolled. The abnormal cell growth is triggered by deoxyribonucleic acid (DNA) damage, including deletions in the DNA section, inactivation of tumor suppressor genes, activation of proto-oncogenes to oncogenes, the absence of apoptosis, and the activity of the telomerase enzyme.<sup>1</sup>

Cigarette smoking is the number one risk factor for lung cancer. Other risk factors for lung cancer are radiation and air pollution. In addition, nutrition and

genetics also play a role in the onset of lung cancer.<sup>1</sup>

In general, lung cancer is divided into two types, namely non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). SCLC has more aggressive behavior and has a worse prognosis. Even though, epidemiologically, NSCLC is more frequently found, about 85% of total lung cancer cases. World Health Organization (WHO) classifies lung cancer into 4 major cell types, namely SCLC, NSCLC which includes adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma (LCC). Histologically, tumors can occur either from single or mixed types.<sup>1,2</sup>

\*Corresponding author: [yan-e-s@fk.unair.ac.id](mailto:yan-e-s@fk.unair.ac.id)



The initial examination that can be performed to detect lung cancer is a chest X-ray (CXR). CXR is a radiographic projection of the lung which is often used for screening (early detection) of lung disease. Image of chest radiographs will give different results between healthy and unhealthy lungs. The presence of nodules in the CXR may result from malignancies, infections, and other lesion. However, these nodules are not necessarily an indication of lung cancer.<sup>1,3</sup> Further diagnosis using chest computed tomography (CT) is the gold standard for imaging of nodules in the lungs. Once the diagnosis of lung cancer has been made, staging is essential for determining appropriate management of the disease.

Lung cancer management is differentiated to the type of histology and stage. Management of lung cancer consists of surgery, chemotherapy, radiotherapy, and targeted therapy. Current therapeutic determinations are focused more on the molecular features of each cancer. This review covers pathogenesis and pathophysiology, risk factor, clinical manifestation, management, complication and prognosis of lung cancer.

### Pathogenesis

The occurrence of lung cancer is based on the emergence of tumor suppressor genes in the genome (oncogenes). The presence of an initiator changes the tumor suppressor gene by removing (deletion) or inserting (insertion) parts of its base pair. The appearance of the *erbB1* and/or *erbB2* genes plays a role in anti-apoptosis (the mechanism for cells to die naturally, programmed cell death). Changes in the appearance of these genes cause target cells, namely lung cells, to turn into cancer cells with autonomic growth properties.<sup>4,5</sup>

Cigarettes play a very important role as an initiator as well as a promoter of lung cancer. Smoking is also known to be closely related to the occurrence of lung cancer. Therefore, cancer is a genetic disease which at first is limited to target cells and then becomes aggressive in surrounding tissues and even affects other organs.<sup>6-8</sup>

### Causes and Risk Factor

The risk factors for lung cancer are very diverse. 1) Gender. Males have methylation levels in the Ras association domain family member 1 (*RASSF1A*) higher than females. The *RASSF1A* gene is one of the tumor suppressors encoding proteins resembling effector renin-angiotensin-system (*RAS*) protein. If there is methylation that induces the inactivation of expression of these genes, it will cause a loss of inhibition of Cyclin D1. Hence, cell cycle arrest does not occur. This causes cells divide uncontrollably and become cancerous.<sup>9-11</sup>

2) Age. The risk of getting cancer will increase with age. A previous study showed a trend toward a suitable smoking pattern age also affects the occurrence of lung cancer.<sup>12</sup> Population aged 45-49 years old showed the highest methylenetetrahydrofolate reductase (*MTHFR*) gene inactivation than other age groups that are closely related to smoking habits. The 50-64 years old group has the highest gene inactivation in *Cadherin-1* (*CDH1*) and *Glutathione S-transferase P-1* genes (*GSTP1*), while the age group >70 years old has a tendency to inactivate *GSTP1* and *RASSF1A* genes the highest compared to other age groups. This causes the age group over 45 years old to have a higher risk to lung cancer.<sup>12</sup>

3) Family history. This is related to the susceptibility to chromosome 6q23-25. The risk of lung cancer in individuals with a family history of lung cancer first-degree relatives increased by 50% in comparison with those with no family history of developing lung cancer.<sup>12</sup>

4) Smoking. Cigarettes contain various carcinogens that can trigger lung cancer. Carcinogens that are closely related to lung cancer are 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (*NNK*), *N-Nitrosornicotine* (*NNN*), and polycyclic aromatic hydrocarbon (*PAH*).<sup>7</sup>

### Clinical Manifestation

In the early stages, most lung cancers do not show clinical symptoms. If symptoms are present, it means that the patient may be in an advanced stage. If the tumor is localized, the symptoms that can arise are coughing, hemoptysis, and wheezing due to airway obstruction. Sometimes there are cavities such as lung abscesses and atelectasis.<sup>13,14</sup>

On reaching local invasion, the clinical manifestations that appear vary as chest pain, dyspnea due to pleural effusion, invasion of the pericardium, superior vena cava syndrome, Horner's syndrome (facial anhidrosis, ptosis, miosis), hoarseness, due to compression of the recurrent laryngeal nerve and Pancoast's syndrome, due to invasion of the brachial plexus and cervical sympathetic nerves. When it has metastases, manifestations will appear at the location of the metastases such as headache in brain metastases, and bone pain when metastasized in the bones. In addition, cervical and supraclavicular lymphadenopathy will usually appear.<sup>4,13,15</sup>

### Classification

The classification of lung cancer aims to determine the appropriate treatment. The term secondary lung cancer refers to metastasis of other malignancy to

the lung and will not be discussed further in this review.<sup>10,11</sup>

Primary lung cancer is divided into two types, namely NSCLC and SCLC. The difference between the two is that SCLC has a higher aggressiveness than NSCLC. About 85% of lung cancer cases is NSCLC. Histologically, tumors can occur in either single or mixed types.<sup>8,9,16</sup>

SCC is the most common type of diagnosed NSCLC. The morphology of SCC resembles an extrapulmonary tumor that appears as an inflated tumor nest without an intracellular bridge. Keratin often appears in the morphology of SCC tissue. The occurrence of SCC is thought to be influenced by smoking. As the number of smokers decreases, SCC is replaced by adenocarcinoma as the most frequently diagnosed type of NSCLC. Adenocarcinoma most commonly affects women under 60 years old. It has glandular, papillary structure, bronchioalveolar pattern, cell mucin, or poorly differentiated solid pattern. It has a signet ring, clear cell and mucinous type, and fetal adenocarcinoma.<sup>13,17</sup>

SCLC is a neuroendocrine tumor that tends to present as a central mass with endobronchial growth and is strongly associated with smoking. SCLC has cells with a small cytoplasm, a small hyperchromatic nucleus with a

chromatin pattern such as "salt and pepper" and a prominent nucleolus. SCLC often produces specific hormones such as adrenocorticotrophic hormone (ACTH), arginine vasopressin (AVP), atrial natriuretic factor (ANF), and gastrin-releasing peptide (GRP) which are associated with distinctive paraneoplastic syndrome.<sup>7</sup>

LCC tends to appear peripherally and appears as a poorly differentiated carcinoma of the lung composition without evidence of squamous, glandular differentiation, or SCLC on light microscopy. These tumors consist of a large malignant layer of cells associated with necrosis. Variants of LCC include basaloid carcinoma which presents as an endobronchial lesion resembling a high-stage neuroendocrine tumor and an associated lymphoepithelioma-like carcinoma with Epstein-Barr virus (EBV) infection.<sup>7</sup>

### Staging

Current staging system of lung cancer used is based on 8<sup>th</sup> edition of lung cancer staging by the Union Internationale Contre le Cancer (UICC) and American Joint Committee on Cancer (AJCC). This staging system is based on three components, namely tumor, node, and metastasis (TNM). Descriptors and grouping can be seen in Table 1 and 2.<sup>18</sup>

**Table 1.** Definitions for T, N, and M descriptors<sup>19</sup>

Tumour size	Table 1 Changes to T-descriptors based on tumour size; comparing the 8 <sup>th</sup> edition with the 7 <sup>th</sup> . Changes are in <i>italic</i>		Table 3 N-descriptors for the 8 <sup>th</sup> edition, unchanged from the 7 <sup>th</sup> . Permission from <i>Journal of Thoracic Oncology</i>	
	7 <sup>th</sup> edition	8 <sup>th</sup> edition	N-stage	Nodal descriptor
Cannot be assessed, not visualized on imaging	Tx	Tx	Nx	Regional lymph nodes cannot be assessed
No evidence of primary tumour	T0	T0	N0	No regional lymph node metastasis
Carcinoma <i>in situ</i>	Tis	Tis	N1	Metastasis in ipsilateral peribronchial and/or hilar lymph node and intrapulmonary node, including involvement by direct extension
≤1 cm	T1a	T1a	N2	Metastasis in ipsilateral mediastinal and/or subcarinal lymph nodes
>1–2 cm	T1a	<i>T1b</i>	N3	Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral, or contralateral scalene, or supraclavicular lymph node(s)
>2–3 cm	T1b	<i>T1c</i>		
>3–4 cm	T2a	T2a		
>4–5 cm	T2a	<i>T2b</i>		
>5–7 cm	T2b	<i>T2c</i>		
>7 cm	T3	<i>T4</i>		

**Table 4** M-descriptors for the 8<sup>th</sup> edition, with the introduction of M1c denoting extrathoracic metastases. Permission from *Journal of Thoracic Oncology*

M-stage	Descriptor
M0	No distant metastasis
M1a	Separate tumor nodule(s) in a contralateral lobe; pleural nodules or malignant pleural or pericardial effusion
M1b	Single extrathoracic metastasis or involvement of a single distant (non-regional) node
M1c	Multiple extrathoracic metastases in one or several organs

**Table 2.** Grouping of lung cancer staging

T/M	Label	N0	N1	N2	N3
T1	T1a <i>≤1</i>	IA1	IIB	IIIA	IIIB
	T1b <i>&gt;1-2</i>	IA2	IIB	IIIA	IIIB
	T1c <i>&gt;2-3</i>	IA3	IIB	IIIA	IIIB
T2	T2a <i>Cent, Yisc Pl</i>	IB	IIB	IIIA	IIIB
	T2a <i>&gt;3-4</i>	IB	IIB	IIIA	IIIB
	T2b <i>&gt;4-5</i>	IIA	IIB	IIIA	IIIB
T3	T3 <i>&gt;5-7</i>	IIB	IIIA	IIIB	IIIC
	T3 <i>Inv</i>	IIB	IIIA	IIIB	IIIC
	T3 <i>Satell</i>	IIB	IIIA	IIIB	IIIC
T4	T4 <i>&gt;7</i>	IIIA	IIIA	IIIB	IIIC
	T4 <i>Inv</i>	IIIA	IIIA	IIIB	IIIC
	T4 <i>Ipsi Nod</i>	IIIA	IIIA	IIIB	IIIC
M1	M1a <i>Contr Nod</i>	IVA	IVA	IVA	IVA
	M1a <i>Pl Dissem</i>	IVA	IVA	IVA	IVA
	M1b <i>Single</i>	IVA	IVA	IVA	IVA
	M1c <i>Multi</i>	IVB	IVB	IVB	IVB

## Treatment

Cancer treatment is based on the type, size, location, and stage of the cancer, as well as the patient's overall condition. In general, lung cancer treatment is divided into surgery, chemotherapy, radiotherapy, and others.<sup>9</sup> Current guidelines used for the management of lung cancer is National Comprehensive Cancer Network 2021. Here are the modalities for the treatment for lung cancer.

- Surgery

Surgery is performed if the cancer is still on one side of the lung and has not spread to the other side of the lung or other organs (stages I and II). The thoracotomy procedure aims to remove the tumor

and some of the healthy tissue around it. This action is performed to inhibit the spread of cancer cells. Large enough, the thoracic surgeon will perform a lobectomy to remove part of the lung. If the cancer has spread to the entire right or left lung, the doctor will remove one lung as a whole. Lung cancer sufferers can still breathe normally, even with only one lung.<sup>8,9,20</sup>

- Chemotherapy

In advanced cancer, chemotherapy is performed for several weeks or months to kill cancer cells, and inhibit the growth and spread of cancer cells that remain after surgery. Chemotherapy can also be performed before surgery with the aim of making the

cancer shrink, making it easier to remove. Another function of chemotherapy is to relieve cancer symptoms experienced by sufferers.<sup>7,8</sup>

- **Radiotherapy**  
Radiotherapy is a treatment method performed after surgery to kill any remaining cancer cells. When surgery is no longer possible for advanced cancer, radiation therapy aims to relieve symptoms and prevent the spread of cancer.<sup>7-9</sup>
- **Target therapy**  
Target therapy is a tablet drug that directly attacks the growth proteins of cancer cells. This drug is given at an advanced stage, when surgery and radiotherapy cannot be performed to treat cancer. Examples of targeted therapy drugs for lung cancer are protein kinase inhibitors, such as erlotinib and gefitinib.<sup>18</sup>
- **Immunotherapy**<sup>17</sup>  
Immunotherapy is basically classes of drugs that uses the body's immune system to kill cancer cells. This modality usually direct to advanced stage of NSCLC or SCLC. Numerous trials are underway to explore the role and mechanism of immunotherapy in the treatment of lung cancer. A recent study of novel agents, especially the checkpoint inhibitors, have shown promising preliminary results in achieving beneficial and durable treatment.<sup>21</sup>
- **Cryotherapy**  
Cryotherapy is a type of treatment that uses gas with very cold temperatures to shrink tumors or kill cancer cells. Cryotherapy is performed if the cancer has blocked the respiratory tract, making it difficult for the patient to breathe.<sup>12,18</sup>

#### Common Comorbidities in Lung Cancer and Prognosis

Anemia and pleural effusion are common comorbidities which usually present in lung cancer. Anemia may be caused due to complication of lung cancer (e.g., hemoptysis) or other condition. It has the prevalence of 60%. It is associated with a poor prognosis in cancer patients. It interferes with the response to radiation treatment, because it reduces the blood's ability to carry oxygen, leaving tissues deprived of oxygen. It causes tumor hypoxia. Hence, solid tumors are resistant to ionization radiation and some forms of chemotherapy.<sup>19</sup>

Pleural effusion due to lung cancer can occur in all types of histology, but the cause is often adenocarcinoma. Accumulation of effusions in the pleural cavity occurs due to increased vascular permeability due to inflammatory reactions induced by

cancer cell infiltration of the parietal and/or visceral pleura, direct invasion of the tumors adjacent to the pleura, and obstruction of the lymph nodes. The presence of malignant pleural effusion in lung cancer describes a terminal condition (end stage) of malignancy with a poor prognosis.<sup>3,5</sup>

The prognosis of lung cancer is poor. The life expectancy of up to 5 years in patients with SCLC is about 20%, while the extensive stage is very poor <1%. Life expectancy of up to 5 years of NSCLC patients varies by stage, 60-70% of patients with stage I, and <1% in patients with stage IV. NSCLC patients who have metastasized, if not treated, has life expectancy of 6 months. Currently, the life expectancy of patients with NSCLC at an early or advanced stage is increasing, compared to the life expectancy of patients at an early stage when given a platinum-based regimen after resection. Targeted therapy also increases the life expectancy of patients with stage IV. However, in metastatic disease, the results are still disappointing.<sup>15,17,21</sup>

#### SUMMARY

Lung cancer is a rapidly growing, uncontrolled cancer that originates in the lungs and is triggered by DNA damage, including deletions, inactivation of tumor suppressor genes, and activation of proto-oncogenes. Cigarette smoking is the leading risk factor for lung cancer, along with radiation, air pollution, nutrition, and genetics. Lung cancer is divided into two types, NSCLC and SCLC. WHO classifies lung cancer into four major cell types, SCLC, NSCLC, SCC, and LCC.

Detection of lung cancer involves CXR, which can reveal nodules from malignancies, infections, and other lesions. Further diagnosis using chest CT is the gold standard for imaging nodules in the lungs. Management consists of surgery, chemotherapy, radiotherapy, and targeted therapy. Pathogenesis is based on the emergence of tumor suppressor genes, which cause cancer cells to turn into cancerous cells. Risk factors for lung cancer include gender, age, and smoking habits.

#### Acknowledgments

None declared.

#### Conflict of Interest

The authors declared there is no conflict of interest.

#### Funding

This study did not receive any funding.

**Authors' Contributions**

Writing the manuscript, co-coordinating study design, collecting data: YES. Data analysis: YES, PP, IGAMAPP, ANOS, SPWBN. Data interpretation: YES, PP. Revising: PP. Reviewing: WIE, JJD, HS, DJSW. All authors contributed and approved the final version of the manuscript.

**REFERENCES**

1. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. *Clin Chest Med* 2020; 41: 1–24.
2. Waddle MR, Ko SJ, May J, *et al.* Improving Identification of Candidates for Lung Cancer Screening in a High Risk Population. *Lung Cancer* 2020; 148: 79–85.
3. Nemesure B, Albano D, Bilfinger T. Lung Cancer Recurrence and Mortality Outcomes Over a 10-Year Period Using a Multidisciplinary Team Approach. *Cancer Epidemiol* 2020; 68: 101804.
4. Lariscy JT, Hummer RA, Rogers RG. Lung Cancer Mortality among Never-Smokers in the United States: Estimating Smoking-Attributable Mortality with Nationally Representative Data. *Ann Epidemiol* 2020; 45: 5–11.
5. MacRosty CR, Rivera MP. Lung Cancer in Women: A Modern Epidemic. *Clin Chest Med* 2020; 41: 53–65.
6. Tolwin Y, Gillis R, Peled N. Gender and Lung Cancer-SEER-Based Analysis. *Ann Epidemiol* 2020; 46: 14–19.
7. Ang L, Chan CPY, Yau W-P, *et al.* Association between Family History of Lung Cancer and Lung Cancer Risk: A Systematic Review and Meta-Analysis. *Lung Cancer* 2020; 148: 129–137.
8. Walter J, Tufman A, Holle R, *et al.* Differences in Therapy and Survival between Lung Cancer Patients Treated in Hospitals with High and Low Patient Case Volume. *Health Policy* 2020; 124: 1217–1225.
9. Shao W, Zhou Q, Tang X. Current and Emerging Treatment Options for Lung Cancer in Patients with Pre-Existing Connective Tissue Disease. *Pulm Pharmacol Ther* 2020; 63: 101937.
10. Sears CR, Mazzone PJ. Biomarkers in Lung Cancer. *Clin Chest Med* 2020; 41: 115–127.
11. Ahmad AS, Mayya AM. A New Tool to Predict Lung Cancer Based on Risk Factors. *Heliyon* 2020; 6: e03402.
12. Pasquinelli MM, Tammemägi MC, Kovitz KL, *et al.* Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities. *J Thorac Oncol* 2020; 15: 1738–1747.
13. Wang J, Li X, Chen H. Organoid Models in Lung Regeneration and Cancer. *Cancer Lett* 2020; 475: 129–135.
14. Hoy H, Lynch T, Beck M. Surgical Treatment of Lung Cancer. *Crit Care Nurs Clin North Am* 2019; 31: 303–313.
15. Aragon KN. Palliative Care in Lung Cancer. *Clin Chest Med* 2020; 41: 281–293.
16. Adams SJ, Stone E, Baldwin DR, *et al.* Lung Cancer Screening. *Lancet (London, England)* 2023; 401: 390–408.
17. Ramroach S, John M, Joshi A. Lung Cancer Type Classification Using Differentiator Genes. *Gene Reports* 2020; 19: 100647.
18. Ruiz-Cordero R, Devine WP. Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer. *Surg Pathol Clin* 2020; 13: 17–33.
19. Lim W, Ridge CA, Nicholson AG, *et al.* The 8(th) Lung Cancer TNM Classification and Clinical Staging System: Review of the Changes and Clinical Implications. *Quant Imaging Med Surg* 2018; 8: 709–718.
20. Mao Y, Yang D, He J, *et al.* Epidemiology of Lung Cancer. *Surg Oncol Clin N Am* 2016; 25: 439–445.
21. Yuan T, Sun S, Cao Z, *et al.* Prognostic Immunohistochemical Markers for Small Cell Lung Cancer: A Review. *Pathol Res Pract* 2021; 217: 153311.

# Lung Cancer; A Literature Review

---

## ORIGINALITY REPORT

---

15%

SIMILARITY INDEX

13%

INTERNET SOURCES

12%

PUBLICATIONS

%

STUDENT PAPERS

---

## PRIMARY SOURCES

---

1	<a href="http://www.targetedonc.com">www.targetedonc.com</a> Internet Source	1%
2	<a href="http://www.lecturio.com">www.lecturio.com</a> Internet Source	1%
3	<a href="http://www.medicopublication.com">www.medicopublication.com</a> Internet Source	1%
4	<a href="http://worldwidescience.org">worldwidescience.org</a> Internet Source	1%
5	Difilippantonio, S.. "Gene expression profiles in human non-small and small-cell lung cancers", European Journal of Cancer, 200309 Publication	1%
6	<a href="http://www.akademiabaru.com">www.akademiabaru.com</a> Internet Source	1%
7	<a href="http://dailygram.com">dailygram.com</a> Internet Source	1%
8	<a href="http://opensource.com">opensource.com</a> Internet Source	1%

---

[www.projectsinknowledge.com](http://www.projectsinknowledge.com)



9	Internet Source	1 %
10	<a href="http://www.wikidoc.org">www.wikidoc.org</a> Internet Source	1 %
11	<a href="http://studentsrepo.um.edu.my">studentsrepo.um.edu.my</a> Internet Source	1 %
12	<a href="http://www.checkupcancer.com">www.checkupcancer.com</a> Internet Source	1 %
13	Yip, Rowena. "Factors Associated With Lung Cancer Treatment Choices: Current Practice and a Step Towards Precision Medicine", The George Washington University, 2024 Publication	<1 %
14	<a href="http://www.e-whn.org">www.e-whn.org</a> Internet Source	<1 %
15	Yumei Li, Feng Wu, Qi Tan, Mengfei Guo, Pei Ma, Xuan Wang, Shuai Zhang, Juanjuan Xu, Ping Luo, Yang Jin. "The multifaceted roles of FOXM1 in pulmonary disease", Cell Communication and Signaling, 2019 Publication	<1 %
16	<a href="http://eprints.gla.ac.uk">eprints.gla.ac.uk</a> Internet Source	<1 %
17	<a href="http://www.uhnresearch.ca">www.uhnresearch.ca</a> Internet Source	<1 %

18 Xiangbing Zhan, Huiyun Long, Fangfang Gou, Xun Duan, Guangqian Kong, Jia Wu. "A Convolutional Neural Network-Based Intelligent Medical System with Sensors for Assistive Diagnosis and Decision-Making in Non-Small Cell Lung Cancer", Sensors, 2021  
Publication

---

19 [erj.ersjournals.com](http://erj.ersjournals.com)  
Internet Source

---

20 [ses.library.usyd.edu.au](http://ses.library.usyd.edu.au)  
Internet Source

---

21 [www.marketresearch.com](http://www.marketresearch.com)  
Internet Source

---

22 [www.mdpi.com](http://www.mdpi.com)  
Internet Source

---

23 [www.science.gov](http://www.science.gov)  
Internet Source

---

24 Kai-li Huang, Han-Yu Deng, Mingyu Fan, Qiangqiang Zheng, Shanyu Lin, Daxing Zhu, Qinghua Zhou. "The sequence of pulmonary vessels ligation during lobectomy for non-small cell lung cancer: A systematic review and meta-analysis", European Journal of Surgical Oncology, 2021  
Publication

---

25 ZF He, LC Zheng, DY Xie, SS Yu, J Zhao. "Mutational analysis of mitochondrial tRNA genes in patients with lung cancer", *Balkan Journal of Medical Genetics*, 2016  
Publication <1 %

---

26 [garuda.kemdikbud.go.id](http://garuda.kemdikbud.go.id)  
Internet Source <1 %

---

27 [journals.plos.org](http://journals.plos.org)  
Internet Source <1 %

---

28 Gee-Chen Chang, Chao-Hua Chiu, Chong-Jen Yu, Yeun-Chung Chang et al. "Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study", *The Lancet Respiratory Medicine*, 2023  
Publication <1 %

---

29 "Lung Cancer", Springer Science and Business Media LLC, 2023  
Publication <1 %

---

30 Jiaqi Zhang, Lei Liu, Guige Wang, Cheng Huang, Yeye Chen, Ye Zhang, Chao Guo, Shanqing Li. "New perspective to evaluate N1 staging: The peripheral lymph node metastasis status of non-small cell lung cancer", *Thoracic Cancer*, 2019  
Publication <1 %

---

31

Michael Donkor, Harlan P. Jones. "The Proposition of the Pulmonary Route as an Attractive Drug Delivery Approach of Nano-Based Immune Therapies and Cancer Vaccines to Treat Lung Tumors", *Frontiers in Nanotechnology*, 2021

Publication

<1 %

---

Exclude quotes      On

Exclude matches      Off

Exclude bibliography      On